<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933658</url>
  </required_header>
  <id_info>
    <org_study_id>DW-1501-P101</org_study_id>
    <nct_id>NCT02933658</nct_id>
  </id_info>
  <brief_title>Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A non-randomized, two-arm, single-sequence, crossover, open label, multiple oral dosing
      clinical trial to evaluate the safety and the pharmacokinetic drug-drug interaction of
      Telmisartan/Amlodipine and Rosuvastatin in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of Reference 1</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Reference 1</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Reference 2</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Reference 2</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24hour</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Hypertension and Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Reference1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single(Reference1) -&gt; combination(Reference1+Reference2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single(Reference2) -&gt; combination(Reference1+Reference2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Reference1</arm_group_label>
    <arm_group_label>Reference2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <arm_group_label>Reference1</arm_group_label>
    <arm_group_label>Reference2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Reference1</arm_group_label>
    <arm_group_label>Reference2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male who are â‰¥19, &lt;50 years old

          -  Man who weights over 55kg and whose BMI is 18~30(kg/m2)

          -  Man who doesn't have any chronic disease or history of disease

        Exclusion Criteria:

          -  man who has or had any clinically relevant disease of liver, kidney,
             nervous/respiratory/musculoskeletal/cardiovascular/hemato-oncology system or
             neuropsychiatry
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

